These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 29316633)
1. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy. Ramirez A; Crisafulli SG; Rizzuti M; Bresolin N; Comi GP; Corti S; Nizzardo M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316633 [TBL] [Abstract][Full Text] [Related]
2. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820 [TBL] [Abstract][Full Text] [Related]
3. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033 [TBL] [Abstract][Full Text] [Related]
4. Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches. Nizzardo M; Simone C; Dametti S; Salani S; Ulzi G; Pagliarani S; Rizzo F; Frattini E; Pagani F; Bresolin N; Comi G; Corti S Sci Rep; 2015 Jun; 5():11746. PubMed ID: 26123042 [TBL] [Abstract][Full Text] [Related]
5. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872 [TBL] [Abstract][Full Text] [Related]
6. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052 [TBL] [Abstract][Full Text] [Related]
7. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471 [TBL] [Abstract][Full Text] [Related]
9. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells. Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932 [TBL] [Abstract][Full Text] [Related]
10. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy. Kannan A; Jiang X; He L; Ahmad S; Gangwani L Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288 [TBL] [Abstract][Full Text] [Related]
11. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660 [TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574 [TBL] [Abstract][Full Text] [Related]
13. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Chen TH Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694 [TBL] [Abstract][Full Text] [Related]
14. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model. Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343 [TBL] [Abstract][Full Text] [Related]
15. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Wood MJA; Talbot K; Bowerman M Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438 [TBL] [Abstract][Full Text] [Related]
16. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296 [TBL] [Abstract][Full Text] [Related]
17. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677 [TBL] [Abstract][Full Text] [Related]
18. Pathological impact of SMN2 mis-splicing in adult SMA mice. Sahashi K; Ling KK; Hua Y; Wilkinson JE; Nomakuchi T; Rigo F; Hung G; Xu D; Jiang YP; Lin RZ; Ko CP; Bennett CF; Krainer AR EMBO Mol Med; 2013 Oct; 5(10):1586-601. PubMed ID: 24014320 [TBL] [Abstract][Full Text] [Related]
19. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7. Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984 [TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model. Wang J; Bai J; OuYang S; Wang H; Jin Y; Peng X; Ge X; Jiao H; Zou J; He C; Xiao P; Song F; Qu Y Hum Mol Genet; 2022 May; 31(10):1635-1650. PubMed ID: 34888619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]